Novo Holdings Asia's Amit Kakar speaks at the Asia Summit on Global Health in Hong Kong (courtesy HKTDC)

June 4, 2024 09:01 AM EDT

Novo Holdings’ head of Asia on investing in ‘China for China,’ and staying out of biotech (for now)

Amber Tong

Senior Editor

Geopolitical headwinds may have given some foreign life sciences investors pause about investing in China. But for Novo Holdings Asia, it’s a good time to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Holdings’ head of Asia on investing in ‘China for China,’ and staying out of biotech (for now)

Amber Tong

Senior Editor

Sign up to read this article for free.

Updated: Eli Lilly wins long-awaited approval for Alzheimer’s drug

As confidence falls, biopharma companies take precautions with Chinese partnerships, survey finds

Following a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot

Takeda to lay off more employees in Massachusetts

Checkpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says

No­vo Hold­ings’ head of Asia on in­vest­ing in ‘Chi­na for Chi­na,’ and stay­ing out of biotech (for now)

Amber Tong

Senior Editor

Sign up to read this article for free.

more like this

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

Fol­low­ing a piv­otal tri­al fail and lay­offs, Ovid finds it­self in a fa­mil­iar spot

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Check­point Ther­a­peu­tics re­files PD-L1 drug cosi­be­limab af­ter FDA re­jec­tion

'Op­ti­miz­ing R&D struc­ture is al­so on the hori­zon, with­out ex­cep­tion,' new Sum­it­o­mo Phar­ma CEO says

Novo Holdings’ head of Asia on investing in ‘China for China,’ and staying out of biotech (for now)

Updated: Eli Lilly wins long-awaited approval for Alzheimer’s drug

As confidence falls, biopharma companies take precautions with Chinese partnerships, survey finds

Following a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot

Takeda to lay off more employees in Massachusetts

Checkpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection

'Optimizing R&D structure is also on the horizon, without exception,' new Sumitomo Pharma CEO says